Edwards Lifesciences, a leader in structural heart disease and critical care monitoring, has announced significant investments aimed at advancing patient care and supporting long-term growth. On August 26, 2024, Edwards agreed to acquire JenaValve Technology, a company that is a pioneer in the transcatheter treatment of aortic regurgitation (AR). JenaValve’s Trilogy Heart Valve System, currently pending FDA approval expected in late 2025, represents a breakthrough as the first approved therapy for symptomatic, severe AR—a condition that remains largely untreated and affects a growing patient population.
Edwards has also exercised its option to acquire Endotronix, enhancing its structural heart portfolio to include heart failure management solutions. Endotronix’s Cordella, an implantable pulmonary artery pressure sensor recently approved by the FDA, offers early intervention for heart failure patients.
With a combined purchase price of approximately $1.2 billion, these acquisitions are poised to bolster Edwards' leadership in structural heart innovation and address critical unmet needs. Both transactions are pending regulatory approvals and are expected to contribute minimally to revenue in 2025.
